Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AGMB

AgomAb Therapeutics NV ADR

Feb 13 • 04:00PM ET

15.34

-0.32 -2.04 %

Healthcare • Biotechnology • Belgium • NASD

Feb 09, 5:15 PMIPO closing announcement confirmed $200 million in proceeds, fueling after-hours rally.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	0.03M	Perf Week	4.71%
Market Cap	0.46M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-175.49M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	0.00	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	4.71%
Book/sh	7790.32	P/C	0.00	EPS next 5Y	-	ROE	-	52W High	16.20 -5.31%	Perf Year	-
Cash/sh	5918.33	P/FCF	-	EPS past 3/5Y	-141.84% -	ROIC	-	52W Low	12.66 21.17%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.23% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	19.02	EPS Q/Q	-	SMA20	-0.83%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-0.83%	Rel Volume	0.15	Prev Close	15.66
Employees	-	LT Debt/Eq	0.01	Earnings	-	SMA200	-0.83%	Avg Volume	737.72K	Price	15.34
IPO	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	108,997	Change	-2.04%

Feb-09-26 04:05PM	Agomab Announces Closing of Initial Public Offering (GlobeNewswire) +6.55%
Feb-07-26 10:55AM	Agomab indicated to open at $15.50, IPO priced at $16 (TipRanks)
Feb-05-26 07:24PM	Agomab Announces Pricing of Initial Public Offering (GlobeNewswire)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGMB

AgomAb Therapeutics NV ADR

Upgrade your FINVIZ experience